|

Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

RECRUITINGSponsored by University of Michigan Rogel Cancer Center
Actively Recruiting
SponsorUniversity of Michigan Rogel Cancer Center
Started2017-01-01
Est. completion2030-01
Eligibility
Age35 Years – 70 Years
SexMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07645391

Summary

This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.

Eligibility

Age: 35 Years – 70 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* \* Age 35-70 years

  * Capable of providing informed consent
  * Prognosis of \> 5 years if affected by another cancer
  * Patients need one to meet at least one of the following high genetic risk categories:

    * Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53
    * Carrier of mutation in a suspected PCa-related gene: e.g., ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, HOXB13
    * Obligate carriers of the above mutations (e.g. their sisters/daughters have known mutations)
    * Men with any family history of above mutation
    * Family history of breast, prostate, or ovarian cancer in at least 2 individuals, or in 1 individual diagnosed before age 50

Exclusion Criteria:

* \* Anuria

  * Prior diagnosis or treatment for PCa
  * Failure to provide informed consent
  * Life expectancy \< 5 years

Conditions2

CancerProstate Carcinoma

Locations1 site

University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109
Cancer AnswerLine800-865-1125CancerAnswerLine@med.umich.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.